MedTrace Logo

A Study of Ranolazine in ALS

NCT06527222 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-10-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

Conditions

Interventions

DRUG

Ranolazine

500mg twice daily

DRUG

Ranolazine

1000 mg twice daily

DRUG

Placebo

Ranolazine placebo twice daily

Sponsors & Collaborators

  • ALS Association

    collaborator OTHER

  • Swathy Chandrashekhar, MBBS

    lead OTHER

Principal Investigators

  • Jeffrey Statland, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-29
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06527222 on ClinicalTrials.gov